Peptide Schedule
5-Amino-1MQSmall moleculeNo amino acid sequence. Icon reflects category theme only.5-Amino-1MQ
Benefits
About 5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in fat cell metabolism and energy expenditure. It's not technically a peptide — it's a quinolinium salt with a molecular weight of just 159.19 g/mol — but it's widely sold alongside peptides in the research compound market and commonly stacked with fat-loss peptides like AOD-9604 and tesofensine. NNMT was first identified as a therapeutic target for obesity in a landmark 2014 Nature study by Kraus et al., which showed that knocking down NNMT expression in white adipose tissue protected mice from diet-induced obesity by boosting cellular energy expenditure (PMID 24717514). The enzyme works by methylating nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor, and its expression is significantly elevated in the fat tissue and liver of obese individuals. When NNMT activity is high, it depletes both NAD+ precursors and SAM — two molecules the body needs for energy metabolism, DNA repair, and epigenetic regulation. 5-Amino-1MQ was developed by Neelakantan, McHardy, and colleagues at the University of Texas in 2017 as part of a structure-activity relationship study screening quinolinium-based NNMT inhibitors (PMID 28548833). It stood out for its selectivity: it doesn't inhibit related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway, making it a clean pharmacological tool for studying NNMT's role in metabolism. In a 2018 follow-up study, the same group demonstrated that subcutaneous administration of 5-Amino-1MQ to diet-induced obese mice significantly reduced body weight, white adipose tissue mass, and adipocyte size — without affecting food intake or causing observable adverse effects (PMID 29738706). A 2024 study further validated NNMT inhibition as a pharmacological approach, showing dose-dependent improvements in glucose tolerance, insulin sensitivity, and hepatic steatosis in DIO mice treated daily for 28 days (PMID 39161060). Despite these promising preclinical results, no human clinical trials have been conducted. All dosing recommendations circulating online are based on animal data and anecdotal reports from the peptide community.
Who Should Consider 5-Amino-1MQ
- Adults researching non-injectable metabolic support compounds for body composition
- Individuals interested in NNMT inhibition for stubborn adipose tissue
- Researchers studying the NNMT-NAD+-SIRT1 axis in obesity and metabolic syndrome
- People seeking oral alternatives to injectable fat-loss peptides like AOD-9604
- Scientists investigating hepatic steatosis and fatty liver pathology interventions
How 5-Amino-1MQ Works
5-Amino-1MQ works by selectively inhibiting nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine. In obese individuals, NNMT is overexpressed in white adipose tissue and liver, creating a metabolic drain on two critical substrates: SAM (the body's primary methyl donor) and nicotinamide (a precursor for NAD+ biosynthesis). When 5-Amino-1MQ blocks NNMT, intracellular nicotinamide accumulates and gets funneled into the NAD+ salvage pathway via NAMPT, raising NAD+ levels. Higher NAD+ activates SIRT1 and other sirtuin-dependent pathways that promote mitochondrial biogenesis and fatty acid oxidation. Simultaneously, SAM levels rise because it's no longer being consumed by NNMT. Elevated SAM increases histone H3 lysine 4 (H3K4) methylation, which upregulates ornithine decarboxylase (ODC) and spermidine/spermine N1-acetyltransferase (SSAT) expression — enzymes that drive polyamine flux. This polyamine cycling is an energy-expensive futile cycle that burns ATP and increases overall cellular energy expenditure. The net result is a two-pronged metabolic shift: fat cells burn more energy through polyamine cycling and enhanced mitochondrial activity, while lipogenesis (new fat creation) is suppressed. This occurs without changes in food intake, as demonstrated across multiple mouse studies.
What to Expect
No visible changes expected. The compound begins inhibiting NNMT at the cellular level, increasing intracellular NAD+ and SAM. Some users report a subtle uptick in energy or slight GI adjustment. This is a calibration period — assess tolerance before increasing dose.
Metabolic shifts are underway but still largely subclinical. Polyamine cycling and enhanced fatty acid oxidation should be active. Some users report improved energy levels and slightly better workout recovery. Body weight changes are typically minimal at this stage.
This is where animal studies show measurable reductions in adipose tissue mass and adipocyte size. Users may begin noticing changes in body composition — particularly around the midsection. Improvements in fasting glucose and lipid panels may become detectable on bloodwork.
Cumulative effects should be at their peak. In the 28-day mouse study, dose-dependent reductions in body weight, fat mass, and liver triglycerides were well-established by this equivalent timepoint. Users often report the most noticeable body composition changes during this window.
Discontinue use and allow NNMT activity to normalize. Metabolic benefits may persist for 1-2 weeks after the last dose as NAD+ and SAM levels gradually return to baseline. Maintain dietary and exercise habits established during the cycle. Wait 4-8 weeks before starting another round.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mg | Daily |
| Moderate | 100mg | Daily |
| Aggressive | 150mg | Daily |
Note: NNMT inhibitor taken orally in capsule form — not an injectable peptide. No human clinical trials exist. All dosing protocols are extrapolated from preclinical mouse data and community experience. Cycle 8-12 weeks on, 4-8 weeks off. Store capsules at room temperature in a cool, dry place.
How to Inject 5-Amino-1MQ
Take one capsule orally with or without food. Some users report better absorption when taken with a small meal. Morning dosing is preferred to align with daily metabolic activity. No reconstitution, bacteriostatic water, or syringes needed — this is a straightforward oral supplement. Stay consistent with daily dosing for best results. If GI discomfort occurs during the first few days, try taking with food.
Cycling Protocol
Most community protocols recommend 8-12 weeks on followed by 4-8 weeks off. The absence of long-term human safety data makes cycling a precautionary measure rather than an evidence-based one. Start at the lower dose (50 mg/day) for the first 1-2 weeks before increasing. No more than 3 cycles per year is a common recommendation.
Pharmacokinetics
Source: Estimated from the 2024 pharmacokinetic characterization study in DIO mice (PMID 39161060). No human PK data exists. The compound showed adequate oral bioavailability in mice with tissue distribution to adipose and liver compartments.
Loading the interactive decay curve.
Side Effects
Human safety data doesn't exist — all side effect information comes from animal studies and anecdotal reports. In preclinical studies, 5-Amino-1MQ treatment showed no observable adverse effects in mice at standard research doses. Community reports mention occasional mild GI discomfort (nausea, loose stools) during the first few days, which typically resolves. Headaches and mild fatigue have been reported anecdotally. Theoretical concerns include disruption of methylation pathways at high doses, since NNMT plays a role in SAM/NAD+ balance. Long-term effects on liver function, hormonal balance, and cardiovascular health are completely unknown.
Contraindications
- Pregnancy or breastfeeding — no reproductive safety data exists for this compound
- Children and adolescents under 18 — not studied in any pediatric context
- Liver disease or impaired hepatic function — NNMT is highly expressed in liver tissue and inhibition effects are unknown in compromised livers
- Active cancer — NNMT has been implicated in tumor biology with context-dependent effects; inhibition could theoretically promote or suppress growth depending on cancer type
- Individuals taking medications that affect methylation pathways (e.g., methotrexate, folate antagonists)
- Known hypersensitivity to quinolinium compounds
Drug Interactions
- NAD+ precursors (NMN, NR, niacin) — 5-Amino-1MQ increases NAD+ through the salvage pathway; stacking with exogenous precursors may have additive effects but hasn't been studied
- Metformin — both compounds affect energy metabolism through different mechanisms; combined effects on glucose handling are unpredictable without data
- SIRT1 activators (resveratrol) — since NNMT inhibition raises NAD+ and activates SIRT1, combining with direct SIRT1 activators could amplify downstream effects
- Methylation-dependent drugs (methotrexate, azathioprine) — NNMT inhibition alters SAM availability, which could theoretically affect the metabolism of drugs that depend on methyltransferase activity
- Statins and lipid-lowering agents — additive cholesterol-lowering effects are possible given the lipid reductions observed in preclinical models
- Insulin and oral hypoglycemics — NNMT inhibition improves insulin sensitivity in animal models; combined use could increase hypoglycemia risk
Storage & Stability
Related Peptides
References
- Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity (Kraus et al., Nature 2014)PubMed 24717514
- Structure-Activity Relationship for Small Molecule Inhibitors of Nicotinamide N-Methyltransferase (Neelakantan et al., J Med Chem 2017)PubMed 28548833
- Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice (Neelakantan et al., Biochem Pharmacol 2018)PubMed 29738706
- Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (Sci Rep 2022)PubMed 35013352
- Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction (Babula et al., Diabetes Obes Metab 2024)PubMed 39161060